SCHEMBL1448846

SCHEMBL1448846

CC(c1ccc(O)cc1)N(C(=O)O)C(C)(C)C

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ESR1 P03372 9/20 0.42
ESR2 Q92731 8/20 0.42
PDCD1 Q15116 1/20 0.42
CD274 Q9NZQ7 1/20 0.42
SRC P12931 1/20 0.37
ALOX5 P09917 2/20 0.36
CYP3A4 P08684 3/20 0.35
ALDH1A1 P00352 1/20 0.35
BLM P54132 1/20 0.35
CYP2C9 P11712 3/20 0.35
CYP2C19 P33261 2/20 0.35
HSD17B10 Q99714 1/20 0.35
APP P05067 1/20 0.35
LMNA P02545 1/20 0.34
CYP1A2 P05177 1/20 0.34
PGR P06401 1/20 0.34
CHRM2 P08172 1/20 0.34
ADORA3 P0DMS8 1/20 0.34
AR P10275 1/20 0.34
CYP2D6 P10635 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2429212 1.00 ESR1 (0.42) ESR1ESR2PDCD1CD274SRC
SCHEMBL1270470 0.84 ALOX5 (0.51) ALOX5ALDH1A1CYP2C19LMNACYP1A2
SCHEMBL2576026 0.84 ALOX5 (0.51) ALOX5ALDH1A1CYP2C19LMNACYP1A2
SCHEMBL2197076 0.84 ALOX5 (0.51) ALOX5ALDH1A1CYP2C19LMNACYP1A2
SCHEMBL2198695 0.83 MAPT (0.39) ALOX5ALDH1A1CYP2C9LMNAMAPT
SCHEMBL10822232 0.82 SRC (0.41) ESR1ESR2PDCD1CD274SRC
SCHEMBL7647994 0.81 NPY5R (0.46) ESR1ESR2PDCD1CD274CYP3A4
SCHEMBL2239284 0.81 PPARA (0.41) ESR1ALOX5ALDH1A1BLMCYP2C9
SCHEMBL2107176 0.81 PPARA (0.41) ESR1ALOX5ALDH1A1BLMCYP2C9
SCHEMBL2197875 0.81 TYR (0.47) ALOX5ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2385040-A1 Nitrogen-containing heterocyclic derivatives and drugs containing the same as the active ingredient ONO Pharmaceutical Co., Ltd. (JP) 2011-11-09 EP disclosed
US-7910741-B2 Nitrogen-containing heterocyclic derivatives and drugs containing the same as the active ingredient ONO PHARMACEUTICAL CO., LTD. (JP) 2011-03-22 US disclosed
US-20060178399-A1 Nitrogen-containing heterocyclic derivatives and drugs containing the same as the active ingredient ONO PHARMACEUTICAL CO., LTD. (JP) 2006-08-10 US disclosed
EP-1604981-A1 NITROGEN-CONTAINING HETEROCYCLIC DERIVATIVES AND DRUGS CONTAINING THE SAME AS THE ACTIVE INGREDIENT ONO PHARMACEUTICAL CO., LTD. (JP) 2005-12-14 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060178399-A1 Nitrogen-containing heterocyclic derivatives and drugs containing the same as the active ingredient HLA-DRB1, ELANE, MMP8 ESR1 545/4885ESR2 1259/4885PDCD1 748/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.